Skip to main
ZYME
ZYME logo

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 35%
Buy 41%
Hold 24%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks Inc. has received FDA accelerated approval for its therapeutic candidate, zanidatamab, for treating adults with metastatic HER2-positive biliary tract cancer, showcasing a strong 52% objective response rate and a median duration of response of 14.9 months. The approval not only bolsters Zymeworks's clinical standing but also results in a $25 million milestone payment to the company, enhancing its financial position. Furthermore, the drug's promising clinical outcomes, such as a median progression-free survival of 7.2 months and median overall survival ranging from 15.5 to 18.1 months for certain patient groups, suggest strong potential for future growth and revenue generation in the biopharmaceutical market.

Bears say

Zymeworks Inc faces multiple challenges that contribute to a negative outlook, including difficulties in scaling up manufacturing for biparatopic antibodies and potential delays in the timely approval of its lead candidate, zanidatamab. The company has projected a significant net loss of $1.95 per share for full-year 2025, which reflects a deterioration in financial performance with a wider loss reported in Q4 2024 than previously anticipated. Additional concerns include risks related to partnership outcomes, lower commercial uptake than expected, and the possibility of long-term dilution, which further complicate the company's financial prospects.

Zymeworks Inc (ZYME) has been analyzed by 17 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 41% recommend Buy, 24% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 17 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.